Should I buy or sell Deciphera Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DCPH shares. View DCPH analyst ratings or view top-rated stocks .

What is Deciphera Pharmaceuticals' stock price target for 2024?

5 Wall Street analysts have issued 12 month price targets for Deciphera Pharmaceuticals' stock. Their DCPH share price targets range from $16.00 to $30.00. On average, they predict the company's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price. View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts .

How have DCPH shares performed in 2024?

Deciphera Pharmaceuticals' stock was trading at $16.13 on January 1st, 2024. Since then, DCPH shares have decreased by 9.1% and is now trading at $14.67. View the best growth stocks for 2024 here .

Are investors shorting Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,060,000 shares, an increase of 7.3% from the March 15th total of 5,650,000 shares. Based on an average trading volume of 540,200 shares, the days-to-cover ratio is presently 11.2 days. Currently, 12.3% of the shares of the company are short sold. View Deciphera Pharmaceuticals' Short Interest .

When is Deciphera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our DCPH earnings forecast .

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its earnings results on Tuesday, February, 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.04. The business earned $48.30 million during the quarter, compared to the consensus estimate of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative trailing twelve-month return on equity of 49.44%. Deciphera Pharmaceuticals's revenue for the quarter was up 32.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.60) EPS.

What ETFs hold Deciphera Pharmaceuticals' stock?

ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP) , Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA) . ALPS Medical Breakthroughs ETF (SBIO) .

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com . Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA) , Ionis Pharmaceuticals (IONS) , Vertex Pharmaceuticals (VRTX) , Allena Pharmaceuticals (ALNA) , Sorrento Therapeutics (SRNE) , Viking Therapeutics (VKTX) , Iovance Biotherapeutics (IOVA) , SCYNEXIS (SCYX) , Axsome Therapeutics (AXSM) and Exelixis (EXEL) .

When did Deciphera Pharmaceuticals IPO?

Deciphera Pharmaceuticals (DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn , Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, Matthew L Sherman , Steven L Hoerter and Thomas Patrick Kelly . View institutional ownership trends .

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free DCPH Stock Alerts

$14.67

+0.44 (+3.09%)

(As of 04/19/2024 ET)

Compare

Today's Range: $14.05
▼
$14.69
50-Day Range: $14.23
▼
$17.36
52-Week Range: $9.90
▼
$17.73

Volume: 394,292 shs
Average Volume: 524,756 shs
Market Capitalization: $1.19 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.00

Get Deciphera Pharmaceuticals alerts:

Deciphera Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 56.8% Upside
$23.00 Price Target
Short Interest: Bearish
12.26% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.60
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.16) to ($1.74) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.36 out of 5 stars

Medical Sector

284th out of 911 stocks

Pharmaceutical Preparations Industry

120th out of 411 stocks

3.4

Analyst's Opinion

Consensus Rating
Deciphera Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Deciphera Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
12.26% of the float of Deciphera Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Deciphera Pharmaceuticals has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Deciphera Pharmaceuticals has recently increased by 7.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Deciphera Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Deciphera Pharmaceuticals does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Deciphera Pharmaceuticals has received a 50.76% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ripretinib", "Preclinical research services for physical health", and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for Deciphera Pharmaceuticals is -1.60.

2.7

News and Social Media Coverage

News Sentiment
Deciphera Pharmaceuticals has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Deciphera Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for DCPH on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Deciphera Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.43% of the stock of Deciphera Pharmaceuticals is held by insiders.
Percentage Held by Institutions
70.96% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($2.16) to ($1.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Deciphera Pharmaceuticals is -6.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Deciphera Pharmaceuticals is -6.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Deciphera Pharmaceuticals has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

DCPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DCPH Stock News Headlines

April 9, 2024 | businesswire.com

Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum

March 25, 2024 | msn.com

Novo Nordisk strikes deal worth up to $1.1 billion to expand cardio business

April 20, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 24, 2024 | finance.yahoo.com

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

February 27, 2024 | businesswire.com

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

February 12, 2024 | finance.yahoo.com

Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade

February 8, 2024 | finance.yahoo.com

Analysts Are Updating Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Estimates After Its Annual Results

February 7, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for Deciphera Pharmaceuticals on Strong Q4 Performance and Promising Drug Prospects

April 20, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 7, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Deciphera Pharmaceuticals (DCPH), ACADIA Pharmaceuticals (ACAD)

February 7, 2024 | finance.yahoo.com

Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

February 6, 2024 | markets.businessinsider.com

Deciphera Pharmaceuticals: Sustained Growth and Market Expansion Drive Buy Rating

February 6, 2024 | markets.businessinsider.com

Deciphera Pharmaceuticals: Strong Buy Rating on Robust Financials and Promising Pipeline

February 6, 2024 | markets.businessinsider.com

Deciphera Pharmaceuticals, Inc. Q4 Loss beats estimates

February 5, 2024 | msn.com

Deciphera Pharmaceuticals Q4 2023 Earnings Preview

February 2, 2024 | nz.finance.yahoo.com

Seattle woman who returned Costco couch after 2.5 years goes viral, sparks ethics debate

February 1, 2024 | finance.yahoo.com

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024

February 1, 2024 | finance.yahoo.com

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

February 1, 2024 | finance.yahoo.com

Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 31, 2024 | uk.investing.com

Deciphera Pharmaceuticals LLC (DCPH)

January 29, 2024 | finance.yahoo.com

Strong week for Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders doesn't alleviate pain of three-year loss

January 18, 2024 | finance.yahoo.com

Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

January 12, 2024 | businesswire.com

GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern Europe

January 11, 2024 | markets.businessinsider.com

Deciphera Pharmaceuticals: A Strong Buy on Impressive Qinlock Sales and Promising Vimseltinib Prospects

January 9, 2024 | seekingalpha.com

Deciphera: Upside Potential For The Patient Investor

January 8, 2024 | seekingalpha.com

Deciphera Pharmaceuticals: Moving The Needle Where It Counts

January 5, 2024 | businesswire.com

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical ...

See More Headlines

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/06/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:DCPH
CUSIP: N/A
CIK: 1654151
Web: www.deciphera.com
Phone: (781) 209-6400
Fax: N/A
Employees: 355
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $23.00
High Stock Price Target: $30.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +56.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-194,940,000.00
Net Margins: -119.33%
Pretax Margin: -119.07%
Return on Equity: -49.44%
Return on Assets: -38.41%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.80
Quick Ratio: 3.59

Sales & Book Value

Annual Sales: $163.36 million
Price / Sales: 7.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.38 per share
Price / Book: 3.35

Miscellaneous

Outstanding Shares: 80,800,000
Free Float: 77,221,000
Market Cap: $1.19 billion
Optionable: Optionable
Beta: 0.39

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Steven L. Hoerter (Age 53)
President, CEO & Director
Comp: $1.24M
Mr. Thomas Patrick Kelly J.D. (Age 53)
Executive VP, CFO & Treasurer
Comp: $778.85k
Mr. Daniel C. Martin (Age 49)
Senior VP & Chief Commercial Officer
Comp: $711.42k
Dr. Matthew L. Sherman M.D. (Age 68)
Executive VP & Chief Medical Officer
Comp: $865.62k
Dr. Kevin Brodbeck Ph.D.
Senior VP & Chief Technical Officer
Dr. Dashyant Dhanak Ph.D. (Age 63)
Executive VP & Chief Scientific Officer
Jennifer Larson
Senior Vice President of Finance & Investor Relations
Mr. Jeffrey M. Held J.D.
Senior VP & General Counsel
Ms. Lisa Amaya Price
Senior VP & Chief Human Resources Officer
Ms. Jama Pitman (Age 44)
Senior VP & Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DCPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DCPH shares.
View DCPH analyst ratings or view top-rated stocks.
What is Deciphera Pharmaceuticals' stock price target for 2024?: 5 Wall Street analysts have issued 12 month price targets for Deciphera Pharmaceuticals' stock. Their DCPH share price targets range from $16.00 to $30.00. On average, they predict the company's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price.
View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts.
How have DCPH shares performed in 2024?: Deciphera Pharmaceuticals' stock was trading at $16.13 on January 1st, 2024. Since then, DCPH shares have decreased by 9.1% and is now trading at $14.67.
View the best growth stocks for 2024 here.
Are investors shorting Deciphera Pharmaceuticals?: Deciphera Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,060,000 shares, an increase of 7.3% from the March 15th total of 5,650,000 shares. Based on an average trading volume of 540,200 shares, the days-to-cover ratio is presently 11.2 days. Currently, 12.3% of the shares of the company are short sold.
View Deciphera Pharmaceuticals' Short Interest.
When is Deciphera Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our DCPH earnings forecast.
How were Deciphera Pharmaceuticals' earnings last quarter?: Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its earnings results on Tuesday, February, 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.04. The business earned $48.30 million during the quarter, compared to the consensus estimate of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative trailing twelve-month return on equity of 49.44%. Deciphera Pharmaceuticals's revenue for the quarter was up 32.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.60) EPS.

What ETFs hold Deciphera Pharmaceuticals' stock?: ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).ALPS Medical Breakthroughs ETF (SBIO).
What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?: 3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Deciphera Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).
When did Deciphera Pharmaceuticals IPO?: Deciphera Pharmaceuticals (DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.
Who are Deciphera Pharmaceuticals' major shareholders?: Deciphera Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, Matthew L Sherman, Steven L Hoerter and Thomas Patrick Kelly.
View institutional ownership trends.
How do I buy shares of Deciphera Pharmaceuticals?: Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DCPH) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

Deciphera Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)

DCPH Stock Price History

DCPH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DCPH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™